"Lithea a Swedish company working on new ways to treat cancer by delivering medicine directly into tumors, has successfully raised € 850.000 (SEK 9.3 Million) from its current investors. This funding shows strong ongoing support and marks an important step toward testing its treatment in humans. Lithea's platform can be used with many types of cancer drugs and may eventually be applied to other common cancers like breast, lung, and prostate."
"This includes more lab studies to confirm safety and effectiveness, as well as preparations for manufacturing and regulatory approval. LIT1001 is a small pellet filled with the chemotherapy drug doxorubicin. It's designed to be placed directly into bone tumors, specifically targeting osteosarcoma, a rare and aggressive cancer mostly affecting children. By delivering the drug straight into the tumor, LIT1001 aims to fight cancer more effectively while reducing harmful side effects."
Lithea secured €850,000 from existing investors to advance its CaS/HA drug-delivery platform and progress LIT1001 toward clinical testing. The funding will support additional laboratory studies to confirm safety and efficacy, manufacturing preparations, and regulatory planning. LIT1001 is a doxorubicin-filled pellet intended for direct implantation into bone tumors to target osteosarcoma and reduce systemic toxicity. Preclinical animal studies showed a 92% reduction in tumor size and much lower systemic drug levels compared with standard treatment. Lithea has patent protection, an experienced team, and FDA Orphan Drug recognition for LIT1001.
Read at resund Startups
Unable to calculate read time
Collection
[
|
...
]